The effective S-1 enables Tumim Stone Capital to resell shares, creating a persistent overhang. Monitor for any subsequent stock sales by Tumim, which could pressure the stock. The company's transition to biopharma and Entolimod pipeline are the key catalysts to watch, but the equity line structure suggests ongoing dilution risk.
Price Chart
Executive Summary
Valion Bio's S-1 registration statement (File No. 333-297529) became effective on August 12, 2026, under the 1933 Act. This effectiveness allows the company to sell shares under its equity line agreement with Tumim Stone Capital, covering 956,222 shares for resale. The company is transitioning from consumer healthtech to a biopharma focus on Entolimod, a late-stage TLR5 agonist for acute radiation syndrome and oncology, but this filing does not represent new capital for the company — it enables the investor to resell shares.
Key Facts
- S-1 registration (File No. 333-297529) declared effective on August 12, 2026.
- Registration covers 956,222 shares for resale by Tumim Stone Capital under a $50 million equity line agreement.
- Valion Bio (formerly Tivic Health Systems) is transitioning from consumer healthtech to biopharma, focusing on Entolimod (TLR5 agonist).
- Company will not receive proceeds from this resale registration; proceeds come from future stock sales to Tumim.
- Market cap is approximately $1M, making this a micro-cap biotech with high dilution risk.
Financial Impact
Potential dilution of up to 956,222 shares from the equity line, but no new capital raised for the company from this registration. The $50M equity line represents a significant overhang relative to the $1M market cap.
Risk Factors
- Dilution from equity line sales by Tumim Stone Capital
- Micro-cap status ($1M market cap) with limited liquidity and high volatility
- Transition risk from consumer healthtech to biopharma with unproven pipeline
- Potential for further capital raises given the $50M equity line structure
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002641 |
| Document: 9999999995-26-002641-index.html | 9999999995-26-002641 |
| Document: 9999999995-26-002641.txt | 9999999995-26-002641 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.8100 (+9.50%) |
Oct 26, 2026 1d ago | 8-K | $1.15 | awaiting T+20 | — | $0.8100 (−29.31%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.8100 (−15.27%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8100 (+27.68%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8100 (+27.68%) |
Oct 16, 2026 10d ago | S-3 | $1.16 | awaiting T+20 | — | $0.8100 (+30.17%) |
Oct 16, 2026 10d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.8100 (+30.17%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.8100 (−34.15%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.8100 (−44.14%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.8100 (+63.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers